Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Parneet K Cheema

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Current Oncology (Toronto, Ont.)|December 23, 2021
The Evolving Role of Immunotherapy in Stage III Non-Small Cell Lung CancerKirstin Perdrizet, Parneet K Cheema
The Oncologist|March 18, 2023
Feasibility of Point-of-Care Genomic Profiling in the Diagnosis and Treatment of Cancer of Unknown PrimaryXin Wang, Andrea Beharry, Brandon S Sheffield, et al.
Frontiers in Oncology|March 25, 2022
Intracranial Metastatic Disease: Present Challenges, Future OpportunitiesAlyssa Y Li, Karolina Gaebe, Katarzyna J Jerzak, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 18, 2018
Multi-disciplinary proactive follow-up algorithm for patients with advanced NSCLC receiving afatinibParneet K Cheema, Alia Thawer, Joanne Leake, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 20, 2009
Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplantParneet K Cheema, Sahar Zadeh, Vishal Kukreti, et al.
Future Oncology (London, England)|June 7, 2023
Comparison of tumor-agnostic and tumor-specific clinical oncology trial designs: a systematic review and meta-analysisMufiza Farid-Kapadia, Madelyn Barton, Zoe Bider-Canfield, et al.
Current Oncology (Toronto, Ont.)|January 20, 2022
Safety Related to the Timing of Radiotherapy and Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer: A Single Institutional ExperienceMichael C Tjong, Malavan Ragulojan, Ian Poon, et al.
The Oncologist|August 30, 2020
Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung CancerBarbara Melosky, Parneet K Cheema, Anthony Brade, et al.
Current Oncology (Toronto, Ont.)|March 24, 2022
Point of Care Molecular Testing: Community-Based Rapid Next-Generation Sequencing to Support Cancer CareBrandon S Sheffield, Andrea Beharry, Joanne Diep, et al.
Lung Cancer (Amsterdam, Netherlands)|December 9, 2019
Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) modelDaniel Moldaver, Manjusha Hurry, William K Evans, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Current Oncology (Toronto, Ont.)|December 23, 2021
The Evolving Role of Immunotherapy in Stage III Non-Small Cell Lung CancerKirstin Perdrizet, Parneet K Cheema
The Oncologist|March 18, 2023
Feasibility of Point-of-Care Genomic Profiling in the Diagnosis and Treatment of Cancer of Unknown PrimaryXin Wang, Andrea Beharry, Brandon S Sheffield, et al.
Frontiers in Oncology|March 25, 2022
Intracranial Metastatic Disease: Present Challenges, Future OpportunitiesAlyssa Y Li, Karolina Gaebe, Katarzyna J Jerzak, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 18, 2018
Multi-disciplinary proactive follow-up algorithm for patients with advanced NSCLC receiving afatinibParneet K Cheema, Alia Thawer, Joanne Leake, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 20, 2009
Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplantParneet K Cheema, Sahar Zadeh, Vishal Kukreti, et al.
Future Oncology (London, England)|June 7, 2023
Comparison of tumor-agnostic and tumor-specific clinical oncology trial designs: a systematic review and meta-analysisMufiza Farid-Kapadia, Madelyn Barton, Zoe Bider-Canfield, et al.
Current Oncology (Toronto, Ont.)|January 20, 2022
Safety Related to the Timing of Radiotherapy and Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer: A Single Institutional ExperienceMichael C Tjong, Malavan Ragulojan, Ian Poon, et al.
The Oncologist|August 30, 2020
Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung CancerBarbara Melosky, Parneet K Cheema, Anthony Brade, et al.
Current Oncology (Toronto, Ont.)|March 24, 2022
Point of Care Molecular Testing: Community-Based Rapid Next-Generation Sequencing to Support Cancer CareBrandon S Sheffield, Andrea Beharry, Joanne Diep, et al.
Lung Cancer (Amsterdam, Netherlands)|December 9, 2019
Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) modelDaniel Moldaver, Manjusha Hurry, William K Evans, et al.
Pageof 3